757 related articles for article (PubMed ID: 31068147)
1. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
2. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
[TBL] [Abstract][Full Text] [Related]
4. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
[TBL] [Abstract][Full Text] [Related]
5. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
[TBL] [Abstract][Full Text] [Related]
6. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
7. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
8. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Razonable RR
Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
[TBL] [Abstract][Full Text] [Related]
11. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review.
Solano C; Giménez E; Albert E; Piñana JL; Navarro D
J Med Virol; 2023 Aug; 95(8):e29005. PubMed ID: 37526411
[TBL] [Abstract][Full Text] [Related]
12. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
13. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
[TBL] [Abstract][Full Text] [Related]
14. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
15. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
16. Letermovir use may impact on the Cytomegalovirus DNA fragmentation profile in plasma from allogeneic hematopoietic stem cell transplant recipients.
Giménez E; Gozalbo-Rovira R; Albert E; Piñana JL; Solano C; Navarro D
J Med Virol; 2024 Mar; 96(3):e29564. PubMed ID: 38506145
[TBL] [Abstract][Full Text] [Related]
17. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
18. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
19. De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.
Jo H; Kwon DE; Han SH; Min SY; Hong YM; Lim BJ; Lee KH; Jo JH
J Infect Dis; 2020 Apr; 221(9):1480-1487. PubMed ID: 31802131
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation.
Frietsch JJ; Michel D; Stamminger T; Hunstig F; Birndt S; Schnetzke U; Scholl S; Hochhaus A; Hilgendorf I
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019001. PubMed ID: 30671207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]